Please check your internet connection and try again.
# Methycobalime (Methylcobalamin)
## Overview
Methylcobalamin is a biologically active, naturally occurring form of Vitamin B12 (cobalamin). Unlike cyanocobalamin, it does not require conversion by the liver to become active and acts as a cofactor for methionine synthase.
## Primary Indications
* Peripheral neuropathy (diabetic or alcoholic).
* Vitamin B12 deficiency (megaloblastic anemia).
* Adjunctive therapy for neurological disorders.
## Adult Dosing
* **Peripheral Neuropathy:** 500 mcg orally 3 times daily.
* **Severe Deficiency:** 500 mcg intramuscularly (IM) or intravenously (IV) 1–3 times weekly for acute phases, followed by maintenance.
* *Note: Dosing varies significantly by regional prescribing guidelines and severity of deficiency. Always defer to local institutional protocol.*
## Pediatric Dosing
* **Standardized dosing is not well-established.** Dosing is typically weight-based and dependent on the underlying metabolic disorder or deficiency severity. Consult a pediatric specialist or local hematology protocols.
## Dose Adjustments
* **Renal/Hepatic:** No formal dose adjustments; however, patients with severe renal impairment may have altered clearance of cobalamin metabolites. Monitor serum levels.
## Contraindications
* Hypersensitivity to methylcobalamin or any component of the formulation.
* Leber’s hereditary optic neuropathy (may lead to rapid optic atrophy).
## Adverse Effects
* **Common:** Injection site reactions, diarrhea, itching (pruritus), or rash.
* **Rare:** Anaphylaxis, hypokalemia (during initial treatment of megaloblastic anemia due to intense erythropoiesis).
## Key Drug Interactions
* **Chloramphenicol:** May decrease the hematopoietic response to B12.
* **Proton Pump Inhibitors (PPIs) / H2 Blockers:** May decrease oral absorption of B12.
* **Metformin:** Long-term use reduces Vitamin B12 absorption.
* **Colchicine/Neomycin:** May impair intestinal absorption of B12.
## Monitoring
* **Serum B12 levels:** Baseline and periodic monitoring.
* **Complete Blood Count (CBC):** To monitor resolution of megaloblastic anemia (reticulocyte count should rise within 3–5 days).
* **Potassium:** Monitor serum levels, particularly during the first 48 hours of treatment for severe anemia, to identify potential hypokalemia.
## Clinical Pearls
* **Bioavailability:** Methylcobalamin is the neurologically active form; it readily crosses the blood-brain barrier.
* **Route:** Oral supplementation is often sufficient for dietary deficiency, but parenteral administration is required for patients with pernicious anemia or malabsorption syndromes (e.g., GI resection).
* **Sublingual Efficacy:** While often marketed, high-dose oral or sublingual administration relies on passive diffusion once intrinsic factor-mediated pathways are saturated.
***
**Educational Disclaimer:** This information is for educational purposes and does not constitute medical advice. Clinical protocols vary by region and institution. Always verify dosing, contraindications, and drug interactions against current institutional formularies, the patient's electronic health record, or official product labeling before prescribing or administering medication.
